Your A1C is a warning, not a sentence.

The Elevated A1C Stack is a physician supervised oral protocol combining compounded microdose tirzepatide with inositol (myo-inositol and D-chiro-inositol), built for adults with A1C in the prediabetic range (5.7 to 6.4%) who want a proactive, physician supervised approach before the numbers progress. The two compounds work through complementary insulin sensitivity pathways: tirzepatide via dual GLP-1 and GIP receptor agonism, inositol via insulin receptor second messenger support. A board certified MD or DO reviews your intake within 48 hours, baseline labs confirm eligibility, and the full oral stack ships from a licensed compounding pharmacy. Compounded tirzepatide is not an FDA approved finished drug product.

A1C measures average blood glucose over the preceding 90 days through hemoglobin glycation. Standard categories: under 5.7% is normal, 5.7 to 6.4% is prediabetic, and 6.5% or higher (confirmed) is type 2 diabetes. The 5.7 to 6.4% range affects roughly 96 million US adults, most of whom are unaware they are in it. Without intervention, 5 to 10% of people in this range progress to type 2 diabetes per year, with cumulative 10-year progression risk of 30 to 50% depending on additional risk factors.

Most patients on the protocol see A1C improvement, though magnitude varies. Published research on tirzepatide at full doses shows A1C reductions in patients with type 2 diabetes; at microdose levels in non-diabetic patients with elevated A1C, observational data and dose-ranging research suggest modest reductions over 12 to 24 weeks. Inositol has clinical research showing improvements in insulin sensitivity measured by HOMA-IR. The protocol is not FDA approved for the treatment of prediabetes, and individual response varies. Your physician monitors A1C trajectory and adjusts the protocol based on your response.

Tirzepatide is a dual GLP-1 and GIP receptor agonist, activating two distinct incretin pathways that govern insulin sensitivity, post-meal glucose response, and satiety. At microdose levels, the protocol supports post-meal glucose stability and insulin sensitivity at lower doses than those required for maximal weight loss. Published dose-ranging data suggest that metabolic effects on glucose handling may occur at lower doses than peak appetite suppression effects. The mechanism does not require significant weight loss to support metabolic benefit. All prescribing decisions are made by the supervising physician based on your clinical profile.

Inositol, specifically the myo-inositol and D-chiro-inositol isomers, is a naturally occurring glucose isomer that acts as a second messenger in insulin receptor signaling. When insulin binds its receptor, inositol-derived molecules carry the signal forward to drive glucose uptake into cells. Clinical research shows inositol supports insulin sensitivity independently of receptor agonism, which makes it mechanistically complementary to tirzepatide rather than redundant. Inositol is included as a non-prescription adjunct in the physician supervised protocol.

For most adults in the prediabetic range, yes. The protocol is specifically designed for patients with A1C 5.7 to 6.4%, where insulin sensitivity is already declining but irreversible damage has not occurred. The standard tirzepatide contraindications apply: personal or family history of medullary thyroid carcinoma, MEN2, active pancreatitis, severe gastroparesis, and pregnancy. Patients with type 1 diabetes or uncontrolled type 2 diabetes (A1C above 9%) are not candidates. Your physician reviews all contraindications during intake. Individual results will vary.

Generally yes, with physician coordination. Tirzepatide and metformin are commonly used together in clinical practice for type 2 diabetes management, and the combination is generally well tolerated. For patients in the prediabetic range already on metformin, adding microdose tirzepatide and inositol typically does not require metformin discontinuation. Your physician reviews your full medication list at intake and coordinates with your primary care physician where appropriate. Hypoglycemia risk is low without insulin or sulfonylureas in the picture.

A1C reflects 90-day average blood glucose, so meaningful changes take time. Most patients see partial A1C decline at the 12-week retest with continued improvement at 24 weeks. Fasting glucose improvements often appear earlier, sometimes within 4 to 8 weeks. HOMA-IR (insulin resistance index) typically improves at 8 to 12 weeks. Your physician orders labs at baseline, 12 weeks, and 24 weeks to track response. Individual results vary based on starting A1C, baseline insulin resistance, dose response, and lifestyle factors.

Standard care for elevated A1C is lifestyle advice and a 6-month follow-up, which is the right starting recommendation but rarely sufficient on its own. The Diabetes Prevention Program showed that intensive lifestyle intervention can reduce progression to type 2 diabetes by 58%, but that result required structured group support, weekly engagement, and 7% or more weight loss, which most patients cannot sustain through self-directed advice alone. The Elevated A1C Stack adds physician prescribed pharmacological support for insulin sensitivity that lifestyle alone often cannot reach, particularly in patients whose insulin resistance is genetic or hormonally driven.

Yes. Elevated A1C in adults with normal or borderline BMI is increasingly common, particularly in patients with family history of type 2 diabetes, polycystic ovary syndrome, or hormonal shifts. Insulin resistance is not weight-dependent at the cellular level; it can occur in lean patients whose glucose handling is genetically or hormonally driven. The Elevated A1C Stack is designed to support insulin sensitivity directly, which means lean patients with elevated A1C are appropriate candidates. Weight changes in lean patients are typically minimal. Your physician confirms whether the protocol fits your specific clinical picture.

Tirzepatide is FDA approved for type 2 diabetes (as Mounjaro) and chronic weight management (as Zepbound). It is not FDA approved specifically for prediabetes or type 2 diabetes prevention. Compounded microdose protocols use the same active pharmaceutical ingredient at lower doses through licensed compounding pharmacies under physician supervision; these compounded formulations are not FDA approved finished drug products. Use in patients with elevated A1C is supported by mechanism and published dose-ranging research, not by a dedicated prediabetes indication. Your physician evaluates whether the protocol is clinically appropriate for your specific situation.

Baseline labs are required before initiation: fasting glucose, HbA1c, and a comprehensive metabolic panel. A lipid panel and fasting insulin are commonly added depending on your clinical picture; your physician specifies the exact panel during intake. Repeat labs are scheduled at 12 weeks and 24 weeks to track A1C trajectory, fasting glucose, and HOMA-IR if measured. Some patients add continuous glucose monitoring during the first 30 days for higher-resolution data; this is optional and not required for protocol effectiveness. Lab costs are separate from the monthly subscription.